drug development & manufacturing accelerator
Private Company
Funding information not available
Overview
Quotient Sciences is a specialized CRDMO leveraging its proprietary Translational Pharmaceutics® platform to integrate drug substance, drug product, and clinical testing services under one organization. Founded in 1994, it serves as a strategic partner primarily for emerging biotech and large pharmaceutical companies, aiming to de-risk and accelerate early-stage drug development. The company's model, which features co-located GMP manufacturing and clinical units, enables rapid, adaptive studies that can significantly compress traditional development timelines. Its success is evidenced by a strong portfolio of customer testimonials across various therapeutic areas and complex modalities.
Technology Platform
Translational Pharmaceutics® platform integrating formulation development, real-time adaptive GMP manufacturing, and clinical testing in a single, iterative workflow to accelerate drug development.
Opportunities
Risk Factors
Competitive Landscape
Quotient Sciences competes with large, full-service CROs (e.g., IQVIA, LabCorp) and CMOs (e.g., Lonza, Catalent), as well as niche formulation development shops. Its key differentiator is the deep, operational integration of real-time manufacturing and clinical testing under its Translational Pharmaceutics® platform, a combination that is difficult for disaggregated competitors to match in speed and flexibility.